Your browser doesn't support javascript.
loading
Perspectives on the clinical development of immunotherapy in prostate cancer / 亚洲男科学杂志(英文版)
Asian Journal of Andrology ; (6): 253-259, 2018.
Artigo em Inglês | WPRIM | ID: wpr-1009596
ABSTRACT
Despite impressive survival benefits with immunotherapy in patients with various solid tumors, the full potential of these agents in prostate cancer has yet to be realized. Sipuleucel-T demonstrated a survival benefit in this population, indicating that prostate cancer is an immunoresponsive disease; however, these results have not been matched by other agents. A large trial with ipilimumab in prostate cancer failed to meet its primary objective, and small trials with PD-1/PD-L1 inhibitors did not yield a significant improvement in overall response. However, several late-stage clinical trials are underway with other vaccines in prostate cancer. Reports of clinical benefit with immunotherapies, particularly when used in combination or a select population, have provided the framework to develop sound clinical trials. Understanding immunogenic modulation, antigen spread, biomarkers, and DNA-repair defects will also help mold future strategies. Through rational patient selection and evidence-based combination approaches, patients with prostate cancer may soon derive durable survival benefits with immunotherapies.
Assuntos

Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Assunto principal: Feniltioidantoína / Neoplasias da Próstata / Extratos de Tecidos / Benzamidas / Protocolos de Quimioterapia Combinada Antineoplásica / Vacinas Anticâncer / Antígeno B7-H1 / Antígeno CTLA-4 / Receptor de Morte Celular Programada 1 / Ipilimumab Limite: Animais / Humanos / Masculino Idioma: Inglês Revista: Asian Journal of Andrology Ano de publicação: 2018 Tipo de documento: Artigo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Assunto principal: Feniltioidantoína / Neoplasias da Próstata / Extratos de Tecidos / Benzamidas / Protocolos de Quimioterapia Combinada Antineoplásica / Vacinas Anticâncer / Antígeno B7-H1 / Antígeno CTLA-4 / Receptor de Morte Celular Programada 1 / Ipilimumab Limite: Animais / Humanos / Masculino Idioma: Inglês Revista: Asian Journal of Andrology Ano de publicação: 2018 Tipo de documento: Artigo